JP2017501692A - 治療用ペプチド - Google Patents
治療用ペプチド Download PDFInfo
- Publication number
- JP2017501692A JP2017501692A JP2016536690A JP2016536690A JP2017501692A JP 2017501692 A JP2017501692 A JP 2017501692A JP 2016536690 A JP2016536690 A JP 2016536690A JP 2016536690 A JP2016536690 A JP 2016536690A JP 2017501692 A JP2017501692 A JP 2017501692A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- mica
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 324
- 230000001225 therapeutic effect Effects 0.000 title description 61
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims abstract description 11
- 101710102605 MHC class I polypeptide-related sequence A Proteins 0.000 claims abstract description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 265
- 210000004027 cell Anatomy 0.000 claims description 184
- 150000007523 nucleic acids Chemical class 0.000 claims description 171
- 238000006467 substitution reaction Methods 0.000 claims description 128
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 105
- 102000039446 nucleic acids Human genes 0.000 claims description 98
- 108020004707 nucleic acids Proteins 0.000 claims description 98
- 206010028980 Neoplasm Diseases 0.000 claims description 93
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 90
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 90
- 150000001413 amino acids Chemical class 0.000 claims description 67
- 239000002773 nucleotide Substances 0.000 claims description 64
- 125000003729 nucleotide group Chemical group 0.000 claims description 64
- 210000000822 natural killer cell Anatomy 0.000 claims description 53
- 239000013598 vector Substances 0.000 claims description 46
- 201000011510 cancer Diseases 0.000 claims description 45
- 108010031034 MHC class I-related chain A Proteins 0.000 claims description 40
- 210000004881 tumor cell Anatomy 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 21
- 230000001404 mediated effect Effects 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 229910052720 vanadium Inorganic materials 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 230000003828 downregulation Effects 0.000 claims description 13
- 239000013603 viral vector Substances 0.000 claims description 10
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 claims description 8
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- -1 amine acids Chemical class 0.000 claims description 7
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 241000702421 Dependoparvovirus Species 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102000043129 MHC class I family Human genes 0.000 claims description 5
- 108091054437 MHC class I family Proteins 0.000 claims description 5
- 241000701161 unidentified adenovirus Species 0.000 claims description 5
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- GYKLFBYWXZYSOW-UHFFFAOYSA-N butanoyloxymethyl 2,2-dimethylpropanoate Chemical compound CCCC(=O)OCOC(=O)C(C)(C)C GYKLFBYWXZYSOW-UHFFFAOYSA-N 0.000 claims description 4
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 4
- 238000001415 gene therapy Methods 0.000 claims description 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 108010091666 romidepsin Proteins 0.000 claims description 4
- 229960003452 romidepsin Drugs 0.000 claims description 4
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 229940022399 cancer vaccine Drugs 0.000 claims description 3
- 238000009566 cancer vaccine Methods 0.000 claims description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 3
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 3
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims description 2
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 108010002156 Depsipeptides Proteins 0.000 claims description 2
- 102000003964 Histone deacetylase Human genes 0.000 claims description 2
- 108090000353 Histone deacetylase Proteins 0.000 claims description 2
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 238000011122 anti-angiogenic therapy Methods 0.000 claims description 2
- 229960003094 belinostat Drugs 0.000 claims description 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims description 2
- 229960001467 bortezomib Drugs 0.000 claims description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- GLNWREBYRLDPQP-MHZLTWQESA-N cyclopentyl (2s)-2-[[4-[[8-(hydroxyamino)-8-oxooctanoyl]amino]phenyl]methylamino]-2-phenylacetate Chemical compound C1=CC(NC(=O)CCCCCCC(=O)NO)=CC=C1CN[C@@H](C=1C=CC=CC=1)C(=O)OC1CCCC1 GLNWREBYRLDPQP-MHZLTWQESA-N 0.000 claims description 2
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 claims description 2
- 229950005837 entinostat Drugs 0.000 claims description 2
- 229950002736 marizomib Drugs 0.000 claims description 2
- 238000011242 molecular targeted therapy Methods 0.000 claims description 2
- QOSWSNDWUATJBJ-UHFFFAOYSA-N n,n'-diphenyloctanediamide Chemical compound C=1C=CC=CC=1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 QOSWSNDWUATJBJ-UHFFFAOYSA-N 0.000 claims description 2
- QRGHOAATPOLDPF-VQFNDLOPSA-N nanatinostat Chemical compound N1=CC(C(=O)NO)=CN=C1N1C[C@@H]([C@@H]2NCC=3N=C4C=CC(F)=CC4=CC=3)[C@@H]2C1 QRGHOAATPOLDPF-VQFNDLOPSA-N 0.000 claims description 2
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims description 2
- 229950009215 phenylbutanoic acid Drugs 0.000 claims description 2
- 239000003207 proteasome inhibitor Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 claims description 2
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 2
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims description 2
- 229960000237 vorinostat Drugs 0.000 claims description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 2
- YTXSYWAKVMZICI-PVCZSOGJSA-N 4-(carboxymethyl)-2-[(1r)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid Chemical compound N([C@@H](CC(C)C)B1OC(CC(O)=O)(CC(=O)O1)C(O)=O)C(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl YTXSYWAKVMZICI-PVCZSOGJSA-N 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 claims 1
- 238000011394 anticancer treatment Methods 0.000 claims 1
- 229960003648 ixazomib Drugs 0.000 claims 1
- 229960000604 valproic acid Drugs 0.000 claims 1
- 229910052618 mica group Inorganic materials 0.000 abstract description 133
- 239000000203 mixture Substances 0.000 abstract description 91
- 239000010445 mica Substances 0.000 abstract description 11
- 230000027455 binding Effects 0.000 description 164
- 239000000427 antigen Substances 0.000 description 155
- 238000000034 method Methods 0.000 description 148
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 142
- 108091007433 antigens Proteins 0.000 description 139
- 102000036639 antigens Human genes 0.000 description 139
- 235000001014 amino acid Nutrition 0.000 description 136
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 109
- 108091028043 Nucleic acid sequence Proteins 0.000 description 78
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 72
- 201000010099 disease Diseases 0.000 description 71
- 229940024606 amino acid Drugs 0.000 description 66
- 108090000623 proteins and genes Proteins 0.000 description 61
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 55
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 55
- 210000002966 serum Anatomy 0.000 description 51
- 102000004169 proteins and genes Human genes 0.000 description 47
- 230000014509 gene expression Effects 0.000 description 43
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 42
- 210000002865 immune cell Anatomy 0.000 description 40
- 230000004048 modification Effects 0.000 description 40
- 238000012986 modification Methods 0.000 description 40
- 239000012634 fragment Substances 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 37
- 125000000539 amino acid group Chemical group 0.000 description 33
- 108060003951 Immunoglobulin Proteins 0.000 description 31
- 239000011324 bead Substances 0.000 description 31
- 239000003814 drug Substances 0.000 description 31
- 102000018358 immunoglobulin Human genes 0.000 description 31
- 201000001441 melanoma Diseases 0.000 description 31
- 210000001806 memory b lymphocyte Anatomy 0.000 description 30
- 102100027641 DNA-binding protein inhibitor ID-1 Human genes 0.000 description 26
- 238000000684 flow cytometry Methods 0.000 description 26
- 238000012360 testing method Methods 0.000 description 22
- 238000003556 assay Methods 0.000 description 20
- 239000012636 effector Substances 0.000 description 20
- 210000004602 germ cell Anatomy 0.000 description 20
- 230000013595 glycosylation Effects 0.000 description 20
- 238000006206 glycosylation reaction Methods 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 210000003719 b-lymphocyte Anatomy 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 19
- 238000012217 deletion Methods 0.000 description 19
- 230000037430 deletion Effects 0.000 description 19
- 108700028369 Alleles Proteins 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 238000013459 approach Methods 0.000 description 17
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 17
- 239000013641 positive control Substances 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 108010090804 Streptavidin Proteins 0.000 description 16
- 230000000903 blocking effect Effects 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 230000035772 mutation Effects 0.000 description 16
- 230000000295 complement effect Effects 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 15
- 230000028993 immune response Effects 0.000 description 15
- 230000002163 immunogen Effects 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 14
- 239000002202 Polyethylene glycol Substances 0.000 description 14
- 239000011651 chromium Substances 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 238000013507 mapping Methods 0.000 description 14
- 229920001223 polyethylene glycol Polymers 0.000 description 14
- 238000003780 insertion Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- 239000013642 negative control Substances 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 108010087819 Fc receptors Proteins 0.000 description 11
- 102000009109 Fc receptors Human genes 0.000 description 11
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 11
- 230000009089 cytolysis Effects 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 10
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 10
- 206010027476 Metastases Diseases 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000004422 calculation algorithm Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000009401 metastasis Effects 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 9
- 108010073807 IgG Receptors Proteins 0.000 description 9
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 9
- 102220575709 UDP-glucose 4-epimerase_C220S_mutation Human genes 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 9
- 231100000135 cytotoxicity Toxicity 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 125000005647 linker group Chemical group 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 8
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 8
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 229940072221 immunoglobulins Drugs 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 238000002703 mutagenesis Methods 0.000 description 8
- 231100000350 mutagenesis Toxicity 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102100027207 CD27 antigen Human genes 0.000 description 7
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 7
- 108091008874 T cell receptors Proteins 0.000 description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 238000003118 sandwich ELISA Methods 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 6
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 125000002015 acyclic group Chemical group 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000002738 chelating agent Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000005090 green fluorescent protein Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000013610 patient sample Substances 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 206010069754 Acquired gene mutation Diseases 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229910052693 Europium Inorganic materials 0.000 description 5
- 229940032072 GVAX vaccine Drugs 0.000 description 5
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 5
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 5
- 102000009490 IgG Receptors Human genes 0.000 description 5
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 5
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 102200106422 c.686G>C Human genes 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000000159 protein binding assay Methods 0.000 description 5
- 102220050205 rs370855515 Human genes 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000037439 somatic mutation Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108091008875 B cell receptors Proteins 0.000 description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 108010067902 Peptide Library Proteins 0.000 description 4
- 108010004729 Phycoerythrin Proteins 0.000 description 4
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000006287 biotinylation Effects 0.000 description 4
- 238000007413 biotinylation Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 210000002825 class switched memory b cell Anatomy 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 108091006047 fluorescent proteins Proteins 0.000 description 4
- 102000034287 fluorescent proteins Human genes 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 229960005386 ipilimumab Drugs 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 238000007857 nested PCR Methods 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000003345 scintillation counting Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 102000004503 Perforin Human genes 0.000 description 3
- 108010056995 Perforin Proteins 0.000 description 3
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 3
- 230000009830 antibody antigen interaction Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 238000005462 in vivo assay Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229930192851 perforin Natural products 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 210000003720 plasmablast Anatomy 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 229960000814 tetanus toxoid Drugs 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 102100034608 Angiopoietin-2 Human genes 0.000 description 2
- 108010048036 Angiopoietin-2 Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 102000014447 Complement C1q Human genes 0.000 description 2
- 108010078043 Complement C1q Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 241001251094 Formica Species 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001098769 Homo sapiens Protein disulfide-isomerase A6 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108010086911 MICB antigen Proteins 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108091005461 Nucleic proteins Chemical group 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100037061 Protein disulfide-isomerase A6 Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 102220500314 Toll-like receptor 8_F405A_mutation Human genes 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003302 anti-idiotype Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 201000003970 colon lymphoma Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 239000012893 effector ligand Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 108010038196 saccharide-binding proteins Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 230000009450 sialylation Effects 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 229940055760 yervoy Drugs 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- RZESKRXOCXWCFX-UHFFFAOYSA-N 2-[bis[2-[carboxymethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetic acid Chemical compound CNC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NC RZESKRXOCXWCFX-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- IOJFHZXQSLNAQJ-UHFFFAOYSA-N 4-azido-2,3,5,6-tetrafluorobenzoic acid Chemical compound OC(=O)C1=C(F)C(F)=C(N=[N+]=[N-])C(F)=C1F IOJFHZXQSLNAQJ-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108091007504 ADAM10 Proteins 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000282979 Alces alces Species 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 101001084702 Arabidopsis thaliana Histone H2B.10 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- XFTWUNOVBCHBJR-UHFFFAOYSA-N Aspergillomarasmine A Chemical group OC(=O)C(N)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O XFTWUNOVBCHBJR-UHFFFAOYSA-N 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 108010035053 B7-1 Antigen Proteins 0.000 description 1
- 102000038504 B7-1 Antigen Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101000611570 Bos taurus Prolactin Proteins 0.000 description 1
- 206010006220 Breast cyst Diseases 0.000 description 1
- 206010006272 Breast mass Diseases 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000002086 C-type lectin-like Human genes 0.000 description 1
- 108050009406 C-type lectin-like Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical group [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 101150015280 Cel gene Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 102100034330 Chromaffin granule amine transporter Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 108010076804 DNA Restriction Enzymes Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100039673 Disintegrin and metalloproteinase domain-containing protein 10 Human genes 0.000 description 1
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 102000006471 Fucosyltransferases Human genes 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- IQUHNCOJRJBMSU-UHFFFAOYSA-N H3HP-DO3A Chemical compound CC(O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 IQUHNCOJRJBMSU-UHFFFAOYSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101710182312 High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 1
- 101000641221 Homo sapiens Chromaffin granule amine transporter Proteins 0.000 description 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001011906 Homo sapiens Matrix metalloproteinase-14 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010023804 Large intestine perforation Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 206010025671 Malignant melanoma stage IV Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000428199 Mustelinae Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102100029812 Protein S100-A12 Human genes 0.000 description 1
- 101710110949 Protein S100-A12 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102220562703 Protein Tob2_L234A_mutation Human genes 0.000 description 1
- 102220521272 Protein phosphatase 1 regulatory subunit 3C_H435Q_mutation Human genes 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102220513656 Transcription termination factor 1, mitochondrial_F243A_mutation Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical class CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 1
- 101000776133 Viola hederacea Leaf cyclotide 1 Proteins 0.000 description 1
- 101000776083 Viola hederacea Leaf cyclotide 2 Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000000999 acridine dye Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940038872 cell-based cancer vaccine Drugs 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 150000004845 diazirines Chemical class 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- QKSGNWJOQMSBEP-UHFFFAOYSA-N diethyl-[[6-[[4-(hydroxycarbamoyl)phenyl]carbamoyloxymethyl]naphthalen-2-yl]methyl]azanium;chloride Chemical compound [Cl-].C1=CC2=CC(C[NH+](CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 QKSGNWJOQMSBEP-UHFFFAOYSA-N 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 150000008267 fucoses Chemical class 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 101150023212 fut8 gene Proteins 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 125000004474 heteroalkylene group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- MBOMYENWWXQSNW-AWEZNQCLSA-N ixazomib citrate Chemical compound N([C@@H](CC(C)C)B1OC(CC(O)=O)(CC(O)=O)C(=O)O1)C(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MBOMYENWWXQSNW-AWEZNQCLSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical group 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000007856 photoaffinity label Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010017378 prolyl aminopeptidase Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 102200072304 rs1057519530 Human genes 0.000 description 1
- 102220315697 rs1553622313 Human genes 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000035936 sexual power Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007860 single-cell PCR Methods 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229940061261 zolinza Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
本願は、2013年12月6日出願の米国仮特許出願番号第61/913,198号および2014年3月14日出願の米国仮特許出願番号第61/953,588号(これらの全開示内容は引用により本明細書に組み込まれる)に関する利益を主張する。
本発明は、国立衛生研究所による助成金番号P01 AI045757およびP01 CA78378のもと、政府支援により成された。政府は、本発明において特定の権利を有する。
本発明は、ヒト対象に関連した治療用組成物(例えば、ペプチド)に関する。
本開示は、治療上の潜在力を有する抗体に関連した組成物および方法を提供する。
いくつかの例において、本明細書中の治療用組成物は疾病または状態に関連した結合パートナー(例えば、免疫原、抗原および/またはエピトープ)と相互作用(例えば、結合、特異的に結合および/または免疫特異的に結合)することができ、ここで、治療用組成物と結合パートナーとの間の相互作用は、前記状態または疾病に対して前向きな免疫応答(例えば、対象における疾病またはその症状のレベルでの減少)という結果になる。
** 配列は、1個、2個、3個、4個、5個、5個未満または10個未満の保存的アミノ酸置換を含んでよい。
# 配列は、表示した配列、またはその配列と、例えばFR1、FR2、FR3および/またはFR4に対応する領域内に示される配列と(例えば少なくとも)80%、85%、90%、95%、96%、97%、98%、99%,および/または100%の配列同一性を有する、および/またはCDR1、2および/または3に対応する領域内に1個、2個、3個、4個、5個、5個未満または10個未満の保存的アミノ酸修飾を有するバリアントを含む。
## 配列は、表示した配列、またはその配列と(例えば少なくとも)80%、85%、90%、95%、96%、97%、98、99%,および/または100%の配列同一性を有するバリアントを含み、前記配列が対応するAAをコードする。
A.A.#は、VHまたはVLのアミノ酸配列を示す。
Nuc.Acid##は、VHまたはVLの核酸配列を示す。
CDRおよびFR領域を以上で示したが、そのような領域はKabat(Sequences of Proteins of Immunological Interest(National Institutes of Health,Bethesda,Md.,1987および1991))に従って規定されてもよい。抗体または抗原結合断片のアミノ酸番号付けも、Kabatの番号付けに従う。
いくつかの例において、本開示は、開示した(例えば、表1に開示した)ペプチドに対応する(コードする)核酸配列を提供する。これらの配列は、開示されたペプチドに関連したすべての縮重配列、即ち1つの特定のペプチド、及びそのバリアントおよび誘導体をコードする配列を有するすべての核酸を含む。かくして、それぞれの特定の核酸配列が本明細書中で書き出されている訳ではないが、各々すべての配列が、実際には、開示したポリペプチド配列を通じて、本明細書中に開示され、記載されていると理解される。
いくつかの例において、本発明は、MICAおよび細胞内T細胞受容体シグナリングドメイン(Kalos Mら、Sci Transl Med.2011 Aug10;3(95))と免疫特異的に結合するペプチドを含むキメラ抗原受容体(CAR)を提供する。いくつかの態様において、CARは、MICA、細胞外ヒンジドメイン、T細胞受容体膜貫通ドメインおよび細胞内T細胞受容体シグナリングドメインと免疫特異的に結合するペプチドを含む。本発明のさらなる実施形態は、関連核酸、組換え発現ベクター、宿主細胞、細胞集団、抗体またはその抗原結合部分、および本発明のCARに関連する医薬組成物を提供する。
いくつかの例において、本明細書中で開示される治療用組成物は、癌の処置に使用される他の化合物、薬物および/または試薬を含んでよい。そのような化合物、薬物および/または試薬には、例えば、所定の癌に対する免疫応答を刺激する化学療法薬、小分子薬または抗体が含まれ得る。いくつかの例において、治療用組成物には、例えば、本明細書中で開示される1つまたは複数のペプチド、および1つまたは複数の抗CTLA−4抗体またはペプチド、抗PD−1抗体またはペプチド、抗PDL−1抗体またはペプチド、抗OX40(別名、CD134、TNFRSF4、ACT35および/またはTXGP1L)抗体またはペプチド、抗GITR(別名、TNFRSF18、AITRおよび/またはCD357)抗体またはペプチド、抗LAG−3抗体またはペプチド、および/または抗TIM−3抗体またはペプチドが含まれ得る。例えば、いくつかの例において、本明細書中で開示される治療用組成物は、1つまたは複数(例えば、1、2、3、4、5または10未満)化合物と組み合わせることができる。
本明細書に開示される1つまたは複数の疾患または状態(例えば、癌(以下の例では「Y」という。)の処置において医薬として使用するための物質X。
Yの処置のための医薬の製造のための物質Xの使用;および
Yの処置に使用するための物質X。
いくつかの例において、方法は、状態または疾患を有する又は有したヒト対象および状態または疾患に対して陽性の免疫応答を示す又は示したヒト対象を選抜することを含んでよい。いくつかの例において、適切な対象は、例えば、状態もしくは疾患を有する対象、または該状態もしくは疾患を有したが前記疾患もしくはその態様が解消した対象(例えば、同じ状態もしくは疾患を有する他の対象(例えば、大部分の対象)と比較して)、および/または前記状態または疾患を有しつつも延長された期間、例えば無症状の状態で(前記状態もしくは疾患を有する他の対象(例えば、大部分の対象)と比較して)生存する対象(例えば、同じ状態もしくは疾患を有する他の対象(例えば、大部分の対象)と比較して)を含む。いくつかの例において、対象は、状態または疾患に対するワクチン接種を受けた(例えば、以前にワクチン接種されたおよび/またはワクチン接種され、再ワクチン接種された(例えば、追加ワクチン接種を受けた)場合に選抜され得る。
いくつかの例において、本開示は、本明細書中に開示される組成物を対象に投与することを含む処置方法を提供する。対象における癌または癌の症状を処置および/または予防する方法であって、前記対象にMHCクラスIポリペプチド・リレイティッド・シークエンスA(MICA)に免疫特異的に結合するペプチドを含む治療上有効な量の組成物を投与することを含み、前記ペプチドは、5個またはそれ未満の保存的アミノ酸置換を有する表1に示される抗体ID1、6、7、8、9、11または12のVHの相補性決定領域(CDR)3と、5個またはそれ未満の保存的アミノ酸置換を有する表1に示される抗体ID1、6、7、8、9、11または12のVLのCDR3とを含む、方法が提供される。いくつかの実施形態において、癌はMICAの過剰発現と関連する癌である。いくつかの実施形態に、癌は、メラノーマ、肺癌、腎臓癌、卵巣癌、前立腺癌、すい臓癌、胃癌、結腸癌、リンパ腫または白血病である。いくつかの実施形態において、癌はメラノーマである。いくつかの実施形態に、癌は形質細胞悪性腫瘍であり、例えば多発性骨髄腫(MM)またはプラズマ細胞の前悪性の状態である。いくつかの実施形態において、対象は、癌を有していると、又は癌体質であると診断されている。
本発明は、以下の実施例においてさらに詳述されるが、実施例は特許請求の範囲に記載の発明の範囲を限定するものではない。
以下にさらに詳細に記載するように、TTCFを大腸菌に発現させ、BirA酵素による部位特異的モノビオチン化のために、BirA部位をN末端に付加した。タンパク質とビオチン化部位との間に、フレキシブルリンカーを配し、抗体結合の立体障害を抑制する。TTCFを、アニオン交換クロマトグラフィーにより精製し、BirAによりビオチン化し、遊離ビオチンとBirAとをゲルろ過クロマトグラフィーにより分離した。TTCF四量体は、蛍光標識化ストレプトアビジンとビオチン化したTTCF抗原とをモル比1:4でインキュベートすることで調製した。次いで、これらの四量体を、破傷風トキソイド特異記憶B細胞の同定のために、mAbパネルと共に用いた。
Franzら、Blood,118(2):348−357(2011)に記載されたように方法を実施した。細胞を、BD FACS AriaIIセルソーターにて選別した。細胞は単細胞選別された。サンプルを、まず、排除マーカー(exclusion marker)パネル(CD3、CD14、CD16、7AAD)が陰性のCD19+細胞に関してゲーティングし、次いで、高レベルのCD27および中レベルのCD19発現により同定された形質芽球に関してゲーティングし、最後に、四量体+CD19+細胞に関してゲーティングした。
TAATACGACTCACTATAGGTTCGGGGAAGTAGTCCTTGACCAGG(配列番号:19);
TAATACGACTCACTATAGGGATAGAAGTTATTCAGCAGGCACAC(配列番号:20);
TAATACGACTCACTATAGGCGTCAGGCTCAGRTAGCTGCTGGCCGC(配列番号:21)。
四量体と単量体TTCFを比較した。TTCFをAlexa−488で蛍光標識し、次いで、それを単量体の形態で用いる又は未標識ストレプトアビジン(上述)を用いて四量体に変えた。富化されたB細胞を、次いで、同じ濃度の四量体または単量体TTCF−Alexa−488と共にインキュベートした。対照タンパク質(CD80膜近傍ドメイン)を同じ方法で標識化し、四量体としても用いた。
完全にヒト抗体を、オーバーラップPCRを介してIgG重鎖およびカッパ鎖の定常領域を単離した可変セグメントに連結することにより、創出した。抗体を、6〜8日間、CHO−S細胞を用いて、一過性に無血清哺乳動物発現系にて発現させた。抗体はプロテインGおよびゲルろ過クロマトグラフィーを用いて精製した。
MICAに免疫特異的に結合する抗体を、本明細書の方法を用いて開発した。
簡潔には、MICA抗原(UniGene Hs.130838)を、該抗原のモノビオチン化を可能にするC末端BirAタグ(GLNDIFEAQKIEWHE(配列番号:148))を付して発現させた。抗原を、R−フィコエリトリン(PE)で標識化したストレプトアビジン(SA)をモル比4(MICA):1(SA)で用いて四量体化した。末梢血単核球を、GM−CSF発現ベクター(GVAX)を用いて形質導入された自己腫瘍細胞によりワクチン接種された進行期のメラノーマ患者から得て(PNAS 103:9190,2006)、続いて、抗CTLA−4モノクローナル抗体イピリムマブ(ipilimumab)(YERVOY(商標)(Bristol Myers Squibから入手可能))を用いて処理した。末梢血単核球を迅速に融解し、洗浄して、2%ウシ胎児血清が補充されたリン酸緩衝生理食塩水(pH7.2)中で5×106に再懸濁し、約0.1μg/mlの四量体を用いて30分間氷上で染色した。抗体を加えて、クラススイッチした記憶B細胞(CD19+、CD27+、およびIgM−)を同定した。T細胞、ナチュラルキラー細胞、マクロファージおよび死細胞を標識する排除抗体パネルを含めて、バックグラウンドの四量体染色(CD3、CD14、CD16、7−AAD)を低減させた。MICA四量体に結合した単一種のB細胞を8チューブのPCRストリップにてBD FACS AriaIIを用いて選別した。B細胞受容体(BCR)mRNAを、Epicentre Biotechnologies(カタログ番号:MBCL90310)の商用キットを下記する遺伝子特異プライマーと用いて増幅した。
IgG−T7:AATACGACTCACTATAGGTTCGGGGAAGTAGTCCTTGACCAGG
(配列番号:22)
Kappa−T7:TAATACGACTCACTATAGGGATAGAAGTTATTCAGCAGGCACAC
(配列番号:23)
Lambda−T7:TAATACGACTCACTATAGGCGTCAGGCTCAGRTAGCTGCTGGCCGC
(配列番号:24)
VHL−1:TCACCATGGACTG(C/G)ACCTGGA(配列番号:25)
VHL−2:CCATGGACACACTTTG(C/T)TCCAC(配列番号:26)
VHL−3:TCACCATGGAGTTTGGGCTGAGC(配列番号:27)
VHL−4:AGAACATGAAACA(C/T)CTGTGGTTCTT(配列番号:28)
VHL−5:ATGGGGTCAACCGCCATCCT(配列番号:29)
VHL−6:ACAATGTCTGTCTCCTTCCTCAT(配列番号:30)
VkL−1:GCTCAGCTCCTGGGGCTCCTG(配列番号:31)
VkL−2:CTGGGGCTGCTAATGCTCTGG(配列番号:32)
VkL−3:TTCCTCCTGCTACTCTGGCTC(配列番号:33)
VkL−4:CAGACCCAGGTCTTCATTTCT(配列番号:34)
VlL−1:CCTCTCCTCCTCACCCTCCT(配列番号:35)
VlL−2:CTCCTCACTCAGGGCACA(配列番号:36)
VlL−3:ATGGCCTGGA(T/C)C(C/G)CTCTCC(配列番号:37)
CgII:GCCAGGGGGAAGAC(C/G)GATG(配列番号:38)
CkII:TTTCAACTGCTCATCAGATGGCGG(配列番号:39)
ClII:AGCTCCTCAGAGGAGGG(C/T)GG(配列番号:40)
VH−1:CAGGT(G/C)CAGCTGGT(G/A)CAGTC(配列番号:41)
VH−2:CAG(A/G)TCACCTTGAAGGAGTC(配列番号:42)
VH−3:(G/C)AGGTGCAGCTGGTGGAGTC(配列番号:43)
VH−4:CAGGTGCAGCTGCAGGAGTC(配列番号:44)
VH−5:GA(G/A)GTGCAGCTGGTGCAGTC(配列番号:45)
VH−6:CAGGTACAGCTGCAGCAGTC(配列番号:46)
Vk−1:CG(A/C)CATCC(A/G)G(A/T)TGACCCAGT(配列番号:47)
Vk−2:CGAT(A/G)TTGTGATGAC(C/T)CAG(配列番号:48)
Vk−3:CGAAAT(T/A)GTG(T/A)TGAC(G/A)CAGTCT(配列番号:49)
Vk−4:CGACATCGTGATGACCCAGT(配列番号:50)
Vl−1:CCAGTCTGTGCTGACTCAGC(配列番号:51)
Vl−2:CCAGTCTGCCCTGACTCAGC(配列番号:52)
Vl−3:CTCCTATGAGCTGAC(T/A)CAGC(配列番号:53)
CgIII:GAC(C/G)GATGGGCCCTTGGTGGA(配列番号:53)
CkIII:AAGATGAAGACAGATGGTGC(配列番号:55)
ClIII:GGGAACAGAGTGACCG(配列番号:56)
上記プライマーセットに十分ではないが潜在的にカバーされる重鎖可変領域配列をカバーする別の重鎖可変領域フォワードプライマーセットを開発した。以下の代替プライマーを作り出した。
VHL1−58:TCACTATGGACTGGATTTGGA(配列番号:57)
VHL2−5:CCATGGACA(C/T)ACTTTG(C/T)TCCAC(配列番号:58)
VHL3−7:GTAGGAGACATGCAAATAGGGCC(配列番号:59)
VHL3−11:AACAAAGCTATGACATATAGATC(配列番号:60)
VHL3−13.1:ATGGAGTTGGGGCTGAGCTGGGTT(配列番号:61)
VHL3−13.2:AGTTGTTAAATGTTTATCGCAGA(配列番号:62)
VHL3−23:AGGTAATTCATGGAGAAATAGAA(配列番号:63)
VHL4−39:AGAACATGAAGCA(C/T)CTGTGGTTCTT(配列番号:64)
VHL4−61:ATGGACTGGACCTGGAGCATC(配列番号:65)
VHL−9:CCTCTGCTGATGAAAACCAGCCC(配列番号:66)
VH1−3/18:CAGGT(C/T)CAGCT(T/G)GTGCAGTC(配列番号:67)
VH1−45/58:CA(A/G)ATGCAGCTGGTGCAGTC(配列番号:68)
VH2−5:CAG(A/G)TCACCTTGA(A/G)GGAGTCTGGT(配列番号:69)
VH3−9/23/43:GA(A/G)GTGCAGCTG(T/G)TGGAGTC(配列番号:70)
VH3−16:GAGGTACAACTGGTGGAGTC(配列番号:71)
VH3−47:GAGGATCAGCTGGTGGAGTC(配列番号:72)
V4−34:CAGGTGCAGCTACAGCAGTG(配列番号:72)
V4−30−2/39:CAGCTGCAGCTGCAGGAGTC(配列番号:74)
VH7−4−1:CAGGTGCAGCTGGTGCAATC(配列番号:75)
臨床上関連した生物学的特徴を有する追加の抗MICA抗体を、本明細書に記載の方法を用いて開発した。共通の対立遺伝子に反応性のMICA特異的抗体を、細胞性癌ワクチン(GM−CSF形質導入癌細胞、GVAXと称する)およびT細胞イピリムマブ(YERVOY(商標)(Bristol Myers Squibから入手可能))上の阻害性CTLA−4受容体を遮断する抗体を受けた患者において同定した。次いで、MICA四量体を用いて、最も高い血清MICA反応性を示した患者の末梢血単核球からB細胞を単離した。実施例5に概括したように、重鎖および軽鎖配列を、これらのB細胞から単細胞PCRにより決定した。この努力は、北アメリカ人集団に共通する対立遺伝子を認識する抗体の同定をもたらした。
単離した抗MICA抗体CM24002Ab2の自己腫瘍細胞に結合する能力を、フローサイトメトリーにより試験した(図27)。骨髄を患者CM24002から採取し、CM24002Ab2による腫瘍細胞に対する結合性を試験した。腫瘍細胞を、次いで、前記骨髄試料からCD33+ CD34+細胞として同定した。その腫瘍細胞を、次いで、抗MICA抗体CM24002Ab2、陽性対照の商用MICA抗体(BioLegend)または陰性対照の抗体(TTCF特異的)の10μg/mlを用いて染色した。図27で示されるように、CM24002Ab2は、これらの細胞に強く結合した。CM24002Ab2は、非腫瘍細胞(CD16+およびCD3+細胞)に対する結合は示さず、CD14+細胞に対してはバックグラウンドの結合性を示すのみで、これは抗腫瘍特異性を実証するものである(データは示さず)。
単離した抗MICA抗体CM24002Ab2がその同起源受容体NKG2Dを可溶性MICA媒介性ダウンレギュレートする能力を試験した。患者CM24002由来の血清を1:10希釈で用いて、ヒトNK細胞と共に48時間インキュベートした。CM24002Ab2(濃度10μg/ml)、陽性対照の商用MICA抗体(BioLegend)または陰性対照抗体(TTCF特異的)をこれらの培養物へ添加した。NKG2D発現は、フローサイトメトリーにより48時間の時点で評価した(図28)。患者CM24002由来の血清は、NKG2D発現を強くダウンレグレートした(かくして、この受容体を機能しなくする)。CM24002Ab2およびこの陽性対照MICA抗体は、NK細胞によるNKG2Dの表面発現を部分的に回復させた。特異性を実証するために、我々は、細胞を患者の血清に代えて2ng/mlの組換えMICAと共にインキュベートすることにより、上記試験を繰り返した(図29)。CM24002Ab2は、MICA媒介性NKG2D発現のダウンレギュレーションを完全に抑制した一方で、陰性対照の抗体(TTCFに特異的)は効果を示さなかった(図29)。これらのデータは、ヒトMICA抗体がヒトNK細胞上の重要なNKG2D受容体の阻害を抑制し得ることを実証する。
CM24002Ab2が細胞媒介性細胞障害を可能にするかどうかを決定するために、ヒトNK細胞(エフェクター細胞)を48時間、CM24002Ab2、陰性対照の抗体(TTCF特異的)または陽性対照(BioLegend)(すべて10μg/ml)の存在下、組換えMICA(2ng/ml)と共にインキュベートした。48時間後に、細胞を洗浄し、K562腫瘍細胞と20:1、10:1および5:1のエフェクター:標的の比で4時間インキュベートした。NK細胞による標的細胞の特異的な溶解を、K562腫瘍細胞からのサイトゾルタンパク質(LDH)の放出により決定した。MICA抗体が存在しない場合、NK細胞によるK562腫瘍細胞の殺傷はなかった。しかしながら、CM24002Ab2は、陽性対照のマウスMICA抗体よりも、すべてのエフェクター:対照の比で、K562腫瘍細胞のNK細胞媒介性の溶解を大幅に増強した(図30)。K562腫瘍細胞の殺傷が本当にNKG2D経路により(Fc受容体よりも)媒介されることがさらに実証された。上記試験を、さらに2つの実験群(NKG2D用の遮断抗体およびヒトFcブロック用の遮断抗体)を用いて繰り返した。加えて、CM33322Ab29も試験した。データは、CM24002Ab2およびCM33322Ab29の添加が、NK細胞媒介性細胞障害を増強したことを示す。NKG2D遮断抗体を添加した場合、K562細胞の殺傷は生じなかったが、一方で、Fc遮断試薬はほとんど効果がなかった(図31)。これらのデータは、CM24002Ab2およびCM33322Ab29が、NKG2D経路の抗腫瘍機能を回復することを示す。
NKG2D受容体は、MICAのトップのアルファ1およびアルファ2ドメインに結合するため、同一部位に結合する抗体はNKG2D受容体と競合することができ、それによって、NK細胞による腫瘍細胞の殺傷を阻止できる。NKG2D受容体の結合を阻止できないために、アルファ3ドメインに結合する抗体が特に興味深い。同時に、そのような抗体は、腫瘍細胞表面からのMICAのタンパク質分解的切断に干渉し得る。MICAα3ドメインに対する抗MICA抗体の能力は、記述のサイトメトリック・ビーズアッセイを用いて評価した。ビオチン化組換えタンパク質を、ストレプトアビジンビーズ上に捕捉した。ビーズを、次いで、10μg/mlの抗体CM24002Ab2、CM24002Ab4、CM33322Ab11、CM33322Ab29、陰性対照抗体(TTCF特異的)または陽性対照抗体(BioLegend)と共にインキュベートし、続いて、FITC標識化抗ヒトIgG二次抗体と共にインキュベートし、フローサイトメトリーによりビーズに結合したFITC蛍光の定量を行った(図32)。図32に示されるように、CM33322Ab29は、MICAアルファ3ドメインに結合し、それ故に、治療応用に非常に興味深い。
広範囲の癌を標的とし、CM24002Ab2およびCM33322Ab29を用いてそれらの潜在的能力を評価した。多発性骨髄腫(RPMI8226およびXg−1)、卵巣癌(OVCAR3)、急性骨髄性白血病(U937)、メラノーマ(K028)、肺癌(1792および827)、および乳癌(MCF7)細胞を、CM24002Ab2およびCM33322Ab29による標識化に関して試験した。腫瘍細胞を、1%BSAが補充されたPBS中に1×106細胞/mlの濃度で再懸濁し、CM24002Ab2およびCM33322Ab29、並びに陽性対照および陰性対照(それぞれマウスMICA抗体およびTTCF特異抗体)(直接コンジュゲートした)濃度10μg/mlを、4℃で1時間用いて染色した(図33)。CM24002Ab2およびCM33322Ab29は両方とも試験した腫瘍細胞タイプのそれぞれに結合し、試験した細胞株の大部分で商用の陽性対照よりもより強く標識化する。Mel526、K029、RPMI−8226およびMCF−7腫瘍細胞系に対して試験した場合、CM3332Ab28はまた、腫瘍細胞上でMICAを検出する能力を実証した。
CM33322Ab29の対立遺伝子特異性を、商業的に利用可能なLuminexアッセイを用いて評価した。商用の試験キットは、Luminexビーズに直接コンジュゲートされた組換えMICA対立遺伝子(MICA*001、*002、*007、*012、*017、*018、*027、*004、*009、および*015)を含み、その各々は単一試料中で結合を評価することを可能にする固有の蛍光特性を有する。表示したMICA対立遺伝子で被覆したLuminexビーズを、CM33322Ab29、BioLegend陽性対照および陰性対照(TTCF)と共に、10μg/mlにて1時間インキュベートし、続いて、PEコンジュゲートされた抗ヒトIgG二次抗体と共にインキュベートした。表示した抗体との60分間のインキュベーションに続き、抗ヒトPEコンジュ―ゲート二次抗体とのインキュベーション後に、蛍光を、Luminex200機器を用いて測定した(図34)。CM33322Ab29は、商用のアッセイに存在する対立遺伝子の全てに結合することができ、これは、MICAの遺伝子型に関係なく患者に使用できることを示唆する。
腫瘍成長に対する抗MICA抗体の直接的な影響を試験するために、インビトロおよびインビボでの抗MICA抗体の生物活性を、ネズミB16を用いて評価した。この試験のために、B16ネズミメラノーマ細胞を形質導入し、ヒトMICAを発現させた。フローサイトメトリーを用いて、細胞B16表面のMICA発現を検出した(図44)。
腫瘍細胞からのMICAの脱落を低減するCM24002Ab2およびCM33322Ab29の潜在力を試験した。RPMI−8226細胞を、10μg/mlのアイソタイプ対照抗体(TTCF−S1C1)、CM33322Ab29、またはCM24002Ab2の存在下で培養した。48時間後に、細胞を洗浄し、MICA表面の発現をフローサイトメトリーにより測定した。図49で実証されるように、CM24002Ab2およびCM33322Ab29は、MICA脱落RPMI−8226細胞を低減させた。
ヒトU937腫瘍細胞を移植されたSCIDマウスをCM24002Ab2、CM33322Ab28およびCM33322Ab29(1週あたり3×100μgAb)を用いて処置した。処置の1週間後に、3種類の抗体のすべてが、ELISAにより測定されたように腫瘍ホモジネートにおけるsMICAを有意に低減させ(腫瘍容積に対して規格化した)、及び、フローサイトメーターにより測定されたように腫瘍ホモジネートにおける腫瘍細胞表面上でのMICA発現を増加させた(図64a〜b)。
CM33322mAb29、CM33322 11、CM33322mAb4およびCM33322mAb28のエピトープ配列を決定するための試験を行った。簡潔には、MICA*009細胞外ドメインの全長に及ぶ一連の重複ペプチドを含むペプチドアレイにより、エピトープマッピングを行った。前記アレイにおける各ペプチドは、MICA*009参照配列(配列番号:185)由来の20アミノ酸直鎖配列長であり、各々の次の配列は前の配列と10アミノ酸重複している(20aaペプチドは10aaのオフセットを有する)。これらのペプチドを、フレキシブルリンカーを使用してスライドガラスに結合させた。抗体を前記スライドと共にインキュベートし、ペプチド断片に結合した抗体をCy5コンジュゲート抗ヒトIgG抗体で検出した。アレイスポットに対する結合は、GenePixマイクロアレイ・スキャナーにより評価した。結果は、抗体CM33322mAb29、CM33322 11、CM33322mAb4およびCM33322mAb28が、ヒトMICAまたはMICBのアルファ3領域に結合することを示す。
1.MHCクラスIポリペプチド・リレイティッド・シークエンスA(MICA)と免疫特異的に結合するペプチドを含む組成物であって、前記ペプチドが配列番号:176に示されるアミノ酸配列を含むVH相補性決定領域(CDR)3もしくは5個以下の保存的アミノ酸置換を有するそのバリアント、および配列番号:183に示されるアミノ酸配列を含むVLCDR3もしくは5個以下の保存的アミノ酸置換を有するそのバリアントを含む、組成物。
本発明は、その詳細な説明と組合せて記載されるが、前述の記載内容は例示を目的とするものであり、添付する特許請求の範囲により規定される本発明の範囲を限定することを意図するものではない。他の態様、利点および改変は、以下の請求項の範囲内にある。
Claims (30)
- MHCクラスIポリペプチド・リレイティッド・シークエンスA(MICA)と免疫特異的に結合する抗体または抗体断片であって、配列番号:168の配列の重鎖可変領域(VH)に示されるVHCDR1、VHCDR2およびVHCDR3を含むVH、またはVHCDR1、CDR2および/またはCDR3に5個以下の保存的アミノ酸置換を有するそのバリアントを含む、抗体もしくは抗体断片。
- 配列番号:170の配列の軽鎖可変領域(VL)に示されるVLCDR1、VLCDR2およびVLCDR3を含むVL、またはVLCDR1、CDR2および/またはCDR3に5個以下の保存的アミノ酸置換を有するそのバリアントをさらに含む、請求項1に記載の抗体もしくは抗体断片。
- 配列番号:168に示されるアミノ酸配列を含むVH領域、またはそのCDR1、CDR2およびCDR3領域内に5個以下の保存的アミノ酸置換を有し、配列番号:168のFR1、FR2、FR3、FR4領域と少なくとも80%、85%、90%、95%、96%、97%、98%、99%または100%の同一性を有するアミノ酸配列を含む対応するFR1、FR2、FR3、FR4領域を含むそのバリアント;および、
配列番号:170に示されるアミノ酸配列を含むVL領域、またはそのCDR1、CDR2およびCDR3領域内に5個以下の保存的アミノ酸置換を有し、配列番号:170のFR1、FR2、FR3、FR4領域と少なくとも80%、85%、90%、95%、96%、97%、98%、99%または100%の同一性を有するアミノ酸配列を含む対応するFR1、FR2、FR3、FR4を含むそのバリアントを含む、
請求項1または2に記載の抗体または抗体断片。 - 配列番号:168と少なくとも85%、90%、95%、96%、97%、98%または99%の同一性を有するアミノ酸配列を含むVHを含む、請求項1〜3のいずれか一項に記載の抗体または抗体断片。
- 配列番号:170と少なくとも85%、90%、95%、96%、97%、98%または99%の同一性を有するアミノ酸配列を含むVL領域を含む、請求項1〜4のいずれか一項に記載の抗体または抗体断片。
- 前記VH領域が、配列番号:172を含むVHCDR1;
配列番号:174を含むVHCDR2;および、
配列番号:176を含むVHCDR3を含む、
請求項1〜5のいずれか一項に記載の抗体または抗体断片。 - 配列番号:179を含むVLCDR1、
配列番号:181を含むVLCDR2、および
配列番号:183を含むVLCDR3を含むVL領域を含む、
請求項1〜6のいずれか一項に記載の抗体または抗体断片。 - 前記VH領域が配列番号:168に示されるアミノ酸配列を含む、またはCDR範囲外の残基に5個以下の保存的アミノ酸置換を含むそのバリアントを含む、請求項1〜7のいずれか一項に記載の抗体または抗体断片、
- 配列番号:170に示されるアミノ酸配列を含むVL領域、またはCDR範囲外の残基に5個以下の保存的アミノ酸置換を含むそのバリアントを含む、請求項1〜8のいずれか一項に記載の抗体または抗体断片。
- 配列番号:185に示されるアミノ酸配列を含むヒトMHCクラスIポリペプチド・リレイティッド・シークエンスA(MICA)のアミノ酸199〜208に対応する、配列TCRASSFYPR(配列番号:189)の1個、2個、3個、4個、5個、6個、7個、8個、9個またはそれを超えるアミンの酸に結合する、抗体または抗体断片。
- アミノ酸配列TCRASSFYPR(配列番号:189)を含むヒトMHCクラスIポリペプチド・リレイティッド・シークエンスA(MICA)のエピトープに結合する、請求項1〜10のいずれか一項に記載の抗体または抗体断片。
- (a)MICAα3ドメインに結合する;
(b)sMICAレベルを低下させる;
(c)腫瘍細胞からMICAの脱落を阻害する;
(d)NK細胞上のNKG2DレセプターのsMICA媒介性ダウンレギュレーションを阻害する;
(e)腫瘍細胞のNK細胞媒介性細胞溶解を増加させる;または
(f)(a)〜(e)の1つまたは複数の組合せの、請求項1〜11のいずれか一項に記載の抗体または抗体断片。 - 配列番号:168のアミノ酸配列を含むVH;および、配列番号:170のアミノ酸配列を含むVL領域を含む、請求項1〜12のいずれか一項に記載の抗体または抗体断片。
- ヒト抗体、ヒト化抗体またはキメラ抗体である、請求項1〜13のいずれか一項に記載の抗体または抗体断片。
- 請求項1〜14のいずれか一項に記載の抗体または抗体断片を含む医薬組成物。
- 抗癌治療をさらに含む、請求項15に記載の医薬組成物。
- ヒドロキサム酸、ボリノスタット、ヒドロキサミン酸サブエロイルアニリド(SAHA、トリコスタチンA(TSA)、LAQ824、パノビノスタット(LBH589)、ベリノスタット(PXD101)、ITF2357イタルファルマコSpA、環状テトラペプチド、デプシペプチド(ロミデプシン、FK228)、ベンズアミド;エンチノスタット(SNDX−275/MS−275)、MGCD0103、短鎖脂肪酸、バルプロ酸、酪酸フェニル、AN−9、ピバネックス(pivanex)、CHR−3996およびCHR−2845からなる群より選択されるヒストンデアセチラーゼ阻害剤(HDAC)をさらに含む、請求項15または16に記載の医薬組成物。
- ボルテゾミブ、NPI−0052、カルフィルゾミブ(PR−171)、CEP18770およびMLN9708からなる群より選択されるプロテアソーム阻害剤をさらに含む、請求項15〜17のいずれか一項に記載の医薬組成物。
- 抗CTLA−4抗体またはペプチド、抗PD−1抗体またはペプチド、抗PDL−1抗体またはペプチド、抗OX40抗体またはペプチド、抗GITR抗体またはペプチド、抗LAG−3抗体またはペプチド、および抗TIM−3抗体またはペプチドからなる群より選択される1つまたは複数の付加的な試薬をさらに含む、請求項15〜18のいずれか一項に記載の医薬組成物。
- 化学療法、放射線療法、サイトカイン、ケモカインおよび他の生物学的シグナル伝達分子、腫瘍特異的ワクチン、細胞癌ワクチン(例えば、GM−CSF形質導入癌細胞)、腫瘍特異的モノクローナル抗体、自家および他家幹細胞レスキュー(例えば、移植片対腫瘍効果を増大させるためのもの)、分子標的療法、抗脈管形成療法および遺伝子治療からなる群より選択される癌の処置に使用される1つまたは複数の付加的な試薬と共に投与するために処方された、請求項15〜19のいずれか一項に記載の医薬組成物。
- 請求項1〜14のいずれか一項に記載の抗体または抗体断片のVH領域をコードする単離された核酸。
- 配列番号:167と少なくとも約75%、80%、90%、95%または99%の同一性を有するヌクレオチド配列を含む、請求項21の単離された核酸。
- 配列番号:168と少なくとも80%、85%、90%、95%、96%、97%、98%、99%または100%の同一性を有するアミノ酸配列を有するペプチドをコードするヌクレオチド配列を含む、単離された核酸。
- 請求項2〜14のいずれか一項に記載の抗体または抗体断片のVL領域をコードする単離された核酸。
- 配列番号:169と少なくとも約75%、80%、90%、95%または99%の同一性を有するヌクレオチド配列を含む、請求項24の単離された核酸。
- 配列番号:170と少なくとも80%、85%、90%、95%、96%、97%、98%、99%または100%の同一性を有するアミノ酸配列を有するペプチドをコードするヌクレオチド配列を含む、単離された核酸。
- 請求項21〜26のいずれか一項に記載の核酸を含むベクター。
- プラスミドまたはウイルスベクターである、請求項27に記載のベクター。
- 前記ウイルスベクターが、ポックスウイルス、アデノウイルス、レトロウイルス、ヘルペスウイルスおよびアデノ随伴ウィルスからなる群より選択される、請求項28に記載のベクター。
- 対象における癌の処置に使用するための、請求項15〜20のいずれか一項に記載の医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361913198P | 2013-12-06 | 2013-12-06 | |
US61/913,198 | 2013-12-06 | ||
US201461953588P | 2014-03-14 | 2014-03-14 | |
US61/953,588 | 2014-03-14 | ||
PCT/US2014/068862 WO2015085210A1 (en) | 2013-12-06 | 2014-12-05 | Therapeutic peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017501692A true JP2017501692A (ja) | 2017-01-19 |
JP6705746B2 JP6705746B2 (ja) | 2020-06-03 |
Family
ID=52293185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016536690A Active JP6705746B2 (ja) | 2013-12-06 | 2014-12-05 | 治療用ペプチド |
Country Status (13)
Country | Link |
---|---|
US (1) | US10106611B2 (ja) |
EP (1) | EP3077504B1 (ja) |
JP (1) | JP6705746B2 (ja) |
KR (1) | KR20160090904A (ja) |
CN (1) | CN106029694A (ja) |
AU (1) | AU2014360273A1 (ja) |
BR (1) | BR112016012358A2 (ja) |
CA (1) | CA2932767A1 (ja) |
EA (1) | EA201691078A1 (ja) |
ES (1) | ES2755129T3 (ja) |
IL (1) | IL245744A0 (ja) |
MX (1) | MX371187B (ja) |
WO (1) | WO2015085210A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021518140A (ja) * | 2018-03-23 | 2021-08-02 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Micaおよび/またはmicbに対する抗体ならびにそれらの使用 |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2760471B9 (en) | 2011-09-30 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
JP6397886B2 (ja) | 2013-03-15 | 2018-09-26 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 治療用ペプチド |
EP3708189B1 (en) | 2013-07-05 | 2023-11-29 | University of Washington through its Center for Commercialization | Soluble mic neutralizing monoclonal antibody for treating cancer |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
KR102248804B1 (ko) | 2014-03-12 | 2021-05-11 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
CA2939006A1 (en) | 2014-03-14 | 2015-09-17 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
AU2016371639A1 (en) | 2015-12-16 | 2018-06-28 | Merck Sharp & Dohme Llc | Anti-LAG3 antibodies and antigen-binding fragments |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
US11066471B2 (en) | 2016-10-19 | 2021-07-20 | Novelogics Biotechnology Inc. | Antibodies to MICA and MICB proteins |
EP3532091A2 (en) * | 2016-10-29 | 2019-09-04 | H. Hoffnabb-La Roche Ag | Anti-mic antibidies and methods of use |
US10300089B2 (en) * | 2016-11-08 | 2019-05-28 | University Of Central Florida Research Foundation, Inc. | Methods for high scale therapeutic production of memory NK cells |
CN108299557A (zh) * | 2017-01-13 | 2018-07-20 | 杭州翰思生物医药有限公司 | 提高IgG类抗体对FcRn的结合亲和力并延长其血清半衰期的方法 |
WO2018141959A1 (en) | 2017-02-06 | 2018-08-09 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
CN109475617B (zh) * | 2017-02-22 | 2022-05-17 | 天境生物科技(杭州)有限公司 | 抗lag-3抗体及其应用 |
KR20190133213A (ko) | 2017-03-31 | 2019-12-02 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
CN109232738B (zh) * | 2017-07-11 | 2021-11-09 | 南京金斯瑞生物科技有限公司 | 一种抗人ox40单克隆抗体及其应用 |
US20200239577A1 (en) | 2017-10-15 | 2020-07-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2019191676A1 (en) | 2018-03-30 | 2019-10-03 | Bristol-Myers Squibb Company | Methods of treating tumor |
WO2020035345A1 (en) | 2018-08-14 | 2020-02-20 | Innate Pharma | Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
EP4192876A1 (en) | 2020-08-10 | 2023-06-14 | Innate Pharma | Cell surface mica and micb detection using antibodies |
EP4342908A1 (en) * | 2021-06-17 | 2024-03-27 | Fapon Biotech Inc. | Chimeric immunoglobulin |
CN113637077B (zh) * | 2021-10-14 | 2021-12-24 | 尚健单抗(北京)生物技术有限公司 | 一种抗mica的抗体及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07505609A (ja) * | 1991-11-08 | 1995-06-22 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | Cd8結合ドメイン・ペプチド |
JP2008543774A (ja) * | 2005-06-08 | 2008-12-04 | ダナ ファーバー キャンサー インスティテュート | プログラム細胞死1(pd−1)経路を阻害することによる持続感染および癌の処置のための方法および組成物 |
US8182809B1 (en) * | 2008-09-08 | 2012-05-22 | University Of Washington | Methods for treating cancer by inhibiting MIC shedding |
WO2012091564A2 (en) * | 2010-12-27 | 2012-07-05 | Apo-T B.V. | A cross-linking polypeptide that induces apoptosis |
WO2013049517A2 (en) * | 2011-09-30 | 2013-04-04 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
WO2013117647A1 (en) * | 2012-02-07 | 2013-08-15 | Innate Pharma | Mica binding agents |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
WO1988007054A1 (en) | 1987-03-18 | 1988-09-22 | Research Corporation Limited | Complement-binding peptide |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
GB8709290D0 (en) | 1987-04-16 | 1987-05-20 | Secretary Trade Ind Brit | Precision motion slideways |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
AUPN568095A0 (en) | 1995-09-27 | 1995-10-26 | Austin Research Institute, The | Anti-Galalpha(1,3)Gal antibody binding peptides |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
CA2275141A1 (en) | 1996-10-29 | 1998-05-07 | Thomas Spies | Cell stress regulated human mhc class i gene |
EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
JP2002512624A (ja) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
US20090175821A1 (en) | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
ES2269366T3 (es) | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos. |
US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002068615A2 (en) | 2001-02-28 | 2002-09-06 | Fred Hutchinson Cancer Research Center, Inc. | Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives |
US20040115198A1 (en) | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
US6566208B2 (en) | 2001-07-25 | 2003-05-20 | Chartered Semiconductor Manufacturing Ltd. | Method to form elevated source/drain using poly spacer |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7524630B2 (en) | 2002-04-22 | 2009-04-28 | University Of Florida Research Foundation, Inc. | Functionalized nanoparticles and methods of use |
WO2003089616A2 (en) | 2002-04-22 | 2003-10-30 | Fred Hutchinson Cancer Research Center | Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions |
ATE536188T1 (de) | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
US7666417B2 (en) | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
BRPI0411803A (pt) | 2003-06-27 | 2006-05-23 | Abgenix Inc | anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seus usos |
US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
BRPI0506771A (pt) | 2004-01-12 | 2007-05-22 | Applied Molecular Evolution | anticorpo, e, composição farmacêutica |
WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
CA2573192C (en) | 2004-08-04 | 2013-09-10 | Applied Molecular Evolution Inc. | Variant fc regions |
CN105085678B (zh) | 2004-12-21 | 2019-05-07 | 阿斯利康公司 | 血管生成素-2的抗体及其应用 |
US20080148432A1 (en) | 2005-12-21 | 2008-06-19 | Mark Scott Abad | Transgenic plants with enhanced agronomic traits |
WO2007055926A1 (en) | 2005-11-03 | 2007-05-18 | Fred Hutchinson Cancer Research Center | Negative immunomodulation of immune responses by nkg2d-positive cd4+ cells |
DE102006009847A1 (de) | 2006-03-01 | 2007-09-06 | Sweredjuk, Robert, Dr. | Verfahren von Absorbieren von Schadstoffen und Gerüchen |
US20100111973A1 (en) | 2006-09-22 | 2010-05-06 | Glenn Dranoff | Methods for treating mica-related disorders |
CA2664567C (en) | 2006-10-04 | 2016-04-26 | Dana-Farber Cancer Institute, Inc. | Tumor immunity |
CA2900172C (en) | 2007-04-23 | 2018-08-28 | Fred Hutchinson Cancer Research Center | Negative immunomodulation of immune responses by erp5 |
BRPI0811857A2 (pt) | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
WO2011063336A2 (en) | 2009-11-20 | 2011-05-26 | President And Fellows Of Harvard College | Secondary site of antigen stimulation for therapeutic vaccination |
EP2254602B1 (en) | 2008-02-13 | 2018-11-21 | President and Fellows of Harvard College | Continuous cell programming devices |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
US8207497B2 (en) | 2009-05-08 | 2012-06-26 | Ionsense, Inc. | Sampling of confined spaces |
KR101688522B1 (ko) | 2009-12-15 | 2016-12-21 | 삼성전자주식회사 | 안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도 |
US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
US8753640B2 (en) | 2011-05-31 | 2014-06-17 | University Of Washington Through Its Center For Commercialization | MIC-binding antibodies and methods of use thereof |
JP6397886B2 (ja) | 2013-03-15 | 2018-09-26 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 治療用ペプチド |
-
2014
- 2014-12-05 BR BR112016012358A patent/BR112016012358A2/pt not_active Application Discontinuation
- 2014-12-05 CA CA2932767A patent/CA2932767A1/en not_active Abandoned
- 2014-12-05 WO PCT/US2014/068862 patent/WO2015085210A1/en active Application Filing
- 2014-12-05 JP JP2016536690A patent/JP6705746B2/ja active Active
- 2014-12-05 CN CN201480075001.0A patent/CN106029694A/zh active Pending
- 2014-12-05 KR KR1020167017672A patent/KR20160090904A/ko not_active Application Discontinuation
- 2014-12-05 EA EA201691078A patent/EA201691078A1/ru unknown
- 2014-12-05 EP EP14824621.8A patent/EP3077504B1/en active Active
- 2014-12-05 US US15/100,060 patent/US10106611B2/en active Active
- 2014-12-05 ES ES14824621T patent/ES2755129T3/es active Active
- 2014-12-05 MX MX2016007063A patent/MX371187B/es active IP Right Grant
- 2014-12-05 AU AU2014360273A patent/AU2014360273A1/en not_active Abandoned
-
2016
- 2016-05-19 IL IL245744A patent/IL245744A0/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07505609A (ja) * | 1991-11-08 | 1995-06-22 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | Cd8結合ドメイン・ペプチド |
JP2008543774A (ja) * | 2005-06-08 | 2008-12-04 | ダナ ファーバー キャンサー インスティテュート | プログラム細胞死1(pd−1)経路を阻害することによる持続感染および癌の処置のための方法および組成物 |
US8182809B1 (en) * | 2008-09-08 | 2012-05-22 | University Of Washington | Methods for treating cancer by inhibiting MIC shedding |
WO2012091564A2 (en) * | 2010-12-27 | 2012-07-05 | Apo-T B.V. | A cross-linking polypeptide that induces apoptosis |
WO2013049517A2 (en) * | 2011-09-30 | 2013-04-04 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
WO2013117647A1 (en) * | 2012-02-07 | 2013-08-15 | Innate Pharma | Mica binding agents |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021518140A (ja) * | 2018-03-23 | 2021-08-02 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Micaおよび/またはmicbに対する抗体ならびにそれらの使用 |
JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル-マイヤーズ スクイブ カンパニー | Micaおよび/またはmicbに対する抗体ならびにそれらの使用 |
Also Published As
Publication number | Publication date |
---|---|
MX2016007063A (es) | 2016-09-06 |
MX371187B (es) | 2020-01-22 |
ES2755129T3 (es) | 2020-04-21 |
EP3077504A1 (en) | 2016-10-12 |
CN106029694A (zh) | 2016-10-12 |
CA2932767A1 (en) | 2015-06-11 |
EP3077504B1 (en) | 2019-08-14 |
EA201691078A1 (ru) | 2017-01-30 |
US10106611B2 (en) | 2018-10-23 |
WO2015085210A1 (en) | 2015-06-11 |
AU2014360273A1 (en) | 2016-06-02 |
US20170022275A1 (en) | 2017-01-26 |
JP6705746B2 (ja) | 2020-06-03 |
KR20160090904A (ko) | 2016-08-01 |
IL245744A0 (en) | 2016-07-31 |
BR112016012358A2 (pt) | 2017-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6705746B2 (ja) | 治療用ペプチド | |
US10745483B2 (en) | Therapeutic peptides | |
RU2725811C1 (ru) | Антитела против 4-1bb человека и их применение | |
US11384144B2 (en) | T cell receptor-like antibodies specific for a PRAME peptide | |
US10793633B2 (en) | Therapeutic peptides | |
US11505599B2 (en) | T cell receptor-like antibodies specific for Foxp3-derived peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181002 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180928 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190104 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190514 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191011 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200317 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200415 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200514 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6705746 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |